Human papillomavirus vaccination for young survivors of cancer
Mené à l'aide de données portant sur 26 486 témoins et mené aux Etats-Unis entre 2013 et 2018 sur 453 patients ayant survécu à un cancer et achevé leurs traitements depuis au moins 1 an (âge : 9-26 ans), cet essai multicentrique de phase II évalue l'efficacité, du point de vue de la réponse des anticorps, et la sécurité de trois doses du vaccin contre le papillomavirus humain quadrivalent ou nonavalent
Human papillomavirus (HPV) vaccine can prevent six types of cancers and has a strong safety profile. However, only 55% of US adolescents (ie, aged 13–15 years) are up to date on HPV vaccination. This proportion is well below the Healthy People 2030 goal of 80% and coverage for other adolescent vaccines of almost 90%. HPV vaccination rates also decreased notably during the COVID-19 pandemic, a problem that was probably amplified for survivors of cancer. Low uptake of HPV vaccine is an especially pressing problem for adolescent and young adult (AYA) survivors of cancer, whose risk of a new cancer diagnosis is 3–10 times higher than the general population.
The Lancet Child & Adolescent Health , commentaire, 2020